# Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

> **NCT00876850** · PHASE3 · WITHDRAWN · sponsor: **Paratek Pharmaceuticals Inc**

## Conditions studied

- Skin Structures and Soft Tissue Infections

## Interventions

- **DRUG:** PTK 0796
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT00876850
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated
- **Last updated:** 2012-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876850, "Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00876850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*